Reporting from ASCO 2022 Annual Meeting in Chicago, Georgina Long features the metastasis-free survival data from KEYNOTE-716 testing the benefit of adjuvant pembrolizumab vs placebo in stage IIB or IIC melanoma. She also explains the results from the NeoTrio study in resectable BRAF-mutated stage III melanoma with anti-PD1 therapy alone, in sequence with or concurrent with BRAF targeted therapy.

This video was supported with educational grants from Novartis and Roche.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

Produced by the European Society for Medical Oncology
[ Ссылка ]

свернуть